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RESUMEN
Introducción. Las Reacciones Adversas a Medicamentos (RAM) constituyen una importante fuente de 
morbilidad y mortalidad en todo el mundo, generando altos costes económicos. Por ello, el objetivo de 
este estudio fue determinar aquellos tratamientos que producen una mayor cantidad de RAM en la po-
blación general así como conocer los principales síntomas que generan.
Material y métodos. Se realizó un estudio transversal observacional mediante la cumplimentación de un 
cuestionario. Para ello, 510 pacientes fueron encuestados sobre qué patologías tenían diagnosticadas, sus 
tratamientos farmacológicos y las RAM sufridas.
Resultados. Un 26,7% de los pacientes encuestados había sufrido alguna RAM. Obtuvimos resultados 
estadísticamente significativos (p ≤ 0.05) al clasificar a los pacientes según el tratamiento prescrito y el 
número de RAM sufridas para los tratamientos farmacológicos de artrosis, anemia y enfermedades del 
sistema nervioso (ansiedad, depresión, insomnio). Además cuantificamos frecuencias de aparición de 
RAM mayores en aquellos fármacos prescritos contra la artrosis (22,6% de los casos sufrieron RAM), 
anemia (14,28%), alteraciones nerviosas (13,44%) y asma (16%). En cuanto a los síntomas producidos, los 
más frecuentes fueron gastrointestinales (60% de los pacientes) y alteraciones nerviosas (mareos, dolor 
de cabeza, problemas de conciliación del sueño etc, 24,6%).
Discusión. La principal conclusión de nuestro estudio es que aquellos fármacos que producen mayor 
número de RAM están prescritos para el tratamiento de la artrosis, la anemia, las alteraciones nerviosas y 
el asma. Además, los síntomas que aparecen principalmente tras una RAM son alteraciones gastrointes-
tinales y nerviosas. Los profesionales sanitarios deberían estar alerta ante la posible aparición de RAM en 
dichos tratamientos y proporcionar a sus pacientes el empoderamiento necesario para que ellos mismos 
pudieran detectarse RAM. Esto evitaría consecuencias negativas tanto en su estado de salud como en el 
gasto sanitario. 
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ABSTRACT
Objectives. Adverse drug reactions (ADRs) are an important cause of morbidity and mortality world-
wide and generate high health costs. Therefore, the aims of this study were to determine the treatments 
which produce more ADRs in general population and the main symptoms they generate.
Methods. An observational, cross-sectional study consisting in performing a self-rated questionnaire 
was carried out. 510 patients were asked about the treatments, illnesses and ADRs, they had suffered 
from.
Results. 26.7% of patients had suffered from some ADR. Classifying patients according to the type of 
prescribed treatment and studying the number of ADR that they had, we obtained significant differ-
ences (p ≤ 0.05) for treatments against arthrosis, anemia and nervous disorders (anxiety, depression, 
insomnia). Moreover, determining absolute frequencies of these ADRs appearance in each treatment, 
higher frequencies were again for drugs against arthrosis (22.6% of patients treated for arthrosis suffered 
some ADR), anemia (14.28%), nerve disorders (13.44%) and also asthma (16%). Regarding the symptoms 
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produced by ADRs, the most frequent were gastrointestinal (60% 
of patients who suffered an ADR, had gastrointestinal symptoms) 
and nervous alterations (dizziness, headache, sleep disturbances 
etc) (24.6%).
Conclusion. Therapeutic groups which produce more commonly 
ADRs are those for arthrosis, anemia, nervous disorders and asth-
ma. In addition, symptoms which are generated more frequently 
are gastrointestinal and nervous problems. This is in accordance 
with the usual side effects of mentioned treatments. Health profes-
sionals should be informed about it, so that they would be more 
alert about a possible emergence of an ADR in these treatments. 
They also could provide enough information to empower patients 
and thus, they probably could detect ADR events. This would fa-
cilitate ADR detection and would avoid serious consequences gen-
erated to both patients’ health and health economics.
Key words: Adverse drug reaction, drug therapy, symptoms, fre-
quency, chronic disease.
INTRODUCTION
Adverse drug reactions (ADRs) are an important cause of 
morbidity and mortality worldwide1-4 and generate high 
health costs5-7. There are many different definitions but the 
most accepted is granted by the World Health Organization 
(WHO), and is defined as any noxious, undesirable reaction 
that occurs with the doses used routinely in humans for the 
treatment, prophylaxis or diagnosing a disease8-10.
It is estimated that between 1 and 4% of consultations in 
emergency services and about 2.5% of the extra-hospital 
consultations are due to ADRs11. In a study conducted in 
2014 in Czech Republic, it was found that 2.2% of hospital 
admissions were due to an ADR12. On the other hand, be-
tween 0.3 and 6% of hospital admissions and 0.2 and 3% of 
hospital deaths are attributable to ADRs11.
ADR detection and notification is vital since ADR appear-
ance is a significant cause of morbidity, hospitalization and 
extension of its length, increased healthcare spending cost 
and what is more important, patient’s death. Therefore, it 
would be really interesting to determine those treatments 
that generate ADR more often. In this way it could be car-
ried out measures to enhance the precautions in these phar-
macological treatments, the information provided by the 
physicians and thus, to reduce ADR and hence its serious 
consequences.
Moreover, if we would be able to determine the main symp-
toms generated by each ADR, they could be more quickly 
detected. For all these reasons, the aims of our study were to 
determine the treatments which produce more ADR events 
in the population and the main symptoms they generate.
MATERIALS AND METHODS
Methods
An observational, cross-sectional study was carried out be-
tween 1 September and 1 November 2013. This study con-
sisted in performing a self-rated questionnaire completed 
by a sample of 510 randomly distributed people. Patients 
were invited to participate in the study, after hearing a de-
scription of the project and providing verbal consent. 286 
patients were surveyed in a community pharmacy, and 224 
patients in 8 Health Centers placed in different health ar-
eas of Region of Murcia. Among these 8 Health Centers, 
there were: 2 Hospitals, 5 Health Centers and 1 clinic. Two 
of these Care Centers were providing services of private 
healthcare and the remaining 6 were providing public 
healthcare. By developing our study in these health cent-
ers, we covered three health areas of the Region de Murcia: 
health area I (Murcia / West), health area VI (Vega Media of 
the Segura) and health area VII (Murcia / East). In this way, 
we can ensure that we cover a wide range of the popula-
tion, with different cultural and economic level.
Materials
A pilot questionnaire was designed by the research team, 
pretested to suit the aims of the study. The questionnaire 
was structured into two blocks of 3 questions each one. 
Firstly, we asked patients about their illnesses and treat-
ments. They were asked if they took drugs daily, how long 
before they were in chronic treatments and for which ill-
nesses. Secondly, we asked them if they had suffered any 
ADR, if so, which drug generated that ADR and which 
symptoms they had. Data on gender, age, nationality, edu-
cational level and profession were also collected.
Statistical analysis
Results were analyzed using the statistical package SPSS 
19.0 data. It was conducted a univariate analysis which 
consisted in collecting absolute and relative frequencies 
distribution (in percentage), as well as descriptive statistics 
(mean, standard deviation, median, mode) of each variable. 
We also conducted a bivariate comparison of the associa-
tion among all the variables, looking for possible associa-
tions, using Pearson’s Chi-squared test.
RESULTS
The socio-demographic characteristic of the sample are de-
picted in Table 1.
From the initial sum of 510 patients, 364 (71.4%) consumed 
drugs daily. The period of time that these patients were 
consuming drugs daily is shown in Table 2.
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The most consumed drugs were those for hypertension and 
for infections. All treatments prescribed are shown in Table 
3. From 510 patients, 130 (25.5%) said that they had suffered 
from some ADR. However, some of them had suffered from 
more than one ADR, so the total number of ADR events 
was 170.
We study ADR incidence according to three variables: con-
suming or not drugs daily, length and kind of pharmaco-
logical treatment. We found significant differences in ADR 
incidence distribution depending on whether patients con-
sumed drugs daily (p<0.001). In contrast, there were no sig-
nificant differences regarding to the length of the different 
treatments. Therefore, patients with chronic treatment are 
more likely to suffer an ADR, regardless of chronic treat-
ment length.
Studying ADR incidence according to the type of treat-
ment, the highest number of ADRs appeared in patients 
with anti-infective and anti-hypertension treatments, as it 
is shown in Table 4.
However, classifying patients according to the type of pre-
scribed treatment and studying the number of ADR that 
these patients had to the treatment, we obtained different 
results. Using Pearson’s Chi-squared test, we found signifi-
cant differences (p ≤ 0.05) for treatments against arthrosis, 
anemia and nervous disorders (anxiety, depression, insom-
nia). Moreover, determining absolute frequencies of ADR 
appearance in each treatment (in relation to the number of 
patients who consumed it) treatments which showed higher 
frequencies were those against: arthrosis (22.6% of patients 
treated for arthrosis suffered an ADR), anemia (14.3%), 
nervous disorders (13.4%) and asthma (16%). Therefore 
there would be a higher probability of developing an ADR 
for patients with such pharmacological treatments.
Regarding the symptoms produced by different ADRs, 
gastrointestinal disorders were the most frequent (60% of 
patients who suffered an ADR, had gastrointestinal symp-
toms) followed by nervous alterations (dizziness, head-
ache, sleep disturbances etc), (24.6%).
Table 1. Socio-demographic characteristic of the sample
n
Sex
 59% women 41% men 301 women
209 men
Age (years)
Mean age: 53.45
Range: 18-92
≤ 40: 25.1%
41-65: 45.9%
≥ 66: 29%
≤ 40: 128
41-65: 234
≥ 66: 148
Nationality 100% Spanish 510
Educational level
None: 5.5%
Primary: 31.8%
Secondary: 19.6%
University: 43.1%
None: 28
Primary: 162
Secondary: 100
University: 220
Profession
Housewife: 16.3%
Retired: 26.7%
Administrative: 6.5%
Health personnel: 9.6%
Teacher: 5.7%
Other: 35.3%
Housewife: 83
Retired: 136
Administrative: 33
Health personnel: 49
Teacher: 29
Other: 180
Table 2. Chronic treatment length 
Time n %
> 5 years 234 64.3
1-5 years 87 23.9
6 months-1year 21 5.8
3-6 months 10 2.7
1-3 months 5 1.4
<1 month 7 1.9
Total 364 100.0
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Table 3. Treatments consumed by the sum
Patients
Treatment for: n %
Diabetes 59 4.42
Nervous alterations 119 8.91
Arthrosis 84 6.29
Cardiovascular alterations 92 6.89
High blood pressure 219 16.40
Infections 480 35.96
Asthma 25 1.87
Anemia 28 2.10
Other 229 17.15
Total 1335 100.00
Table 4. Number of ADRs which were produced by each treatment
ADR
Treatment for: n %
Diabetes 7 4.12
Nervous alterations 16 9.41
Arthrosis 19 11.18
Cardiovascular alterations 12 7.06
High blood pressure 29 17.06
Infections 30 17.65
Asthma 4 2.35
Anemia 4 2.35
Other 49 28.82
Total 170 100.00
ADR = Adverse drug reactions
Table 5. Significations obtained in the distribution of ADRs appearance in each treatment by using Pearson’s Chi-squared te 
Pearson’s Chi-squared
Treatment for: Value Signification
Diabetes 1.041 0.308
High blood pressure 0.812 0.666
Cardiovascular alterations 0.202 0.653
Infections 0.451 0.502
Anemia 6.113  0.013*
Nervous alterations 6.174  0.013*
Arthrosis 5.312  0.021*
Asthma 0.05 0.946
ADR = Adverse drug reactions
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Table 6. Frequency of symptoms produced by ADRs
Symptoms Cases
% of patients who suffered ADR with 
symptoms
Gastrointestinal disorders 78 60
Nervous alterations 32 24.6
Cardiovascular alterations 9 6.9
Mouth dryness 6 4.6
Movement difficulty 7 5.4
Skin reactions 17 13.1
Other 35 26.9
ADR = Adverse drug reactions
DISCUSSION
Once data from surveys were gathered, we realized the 
great number of patients with chronic treatments (71.4%). 
Thus, to estimate the relation between being in chronic 
treatment and suffering an ADR event could be interesting. 
We did that analysis obtaining that there were more prob-
abilities of suffering an ADR if patients were in a chronic 
treatment. This is because so many drugs generate ADR 
when they are used in a long term. However, there were no 
significant differences regarding the length of the chronic 
treatment.
As it is shown in Results, 170 ADR happened. The number 
of ADR cases was higher for antibiotics (17.65%) and for 
antihypertensive treatment (17.06%). In part, this is because 
these treatments are two of the most administered treat-
ments. In this way, among respondents in our sample, there 
were a great number of patients with these treatments, 480 
surveyed had been in a treatment containing antibiotics 
and 219 in an antihypertensive treatment. Scientific litera-
ture widely documents the current overuse of antibiotics13, 
14 and recent studies have determined that antibiotics are 
the most frequently prescribed drugs15. On the other hand, 
high blood pressure is a major public health problem and 
a leading risk factor for cardiovascular disease and mor-
tality16-18. One-quarter of the world’s adult population has 
hypertension16 and more than 7 million of deaths can be 
attributed to the effects of hypertension17. At 65 years, indi-
viduals have a 90% chance of developing hypertension at 
the time they reach 80 years of age17. Therefore, being these 
two treatments so much used, the incidence of an ADR 
event seems to be higher.
Then, we had to relate ADR incidence of each treatment and 
the number of patients in that treatment. Thus, it is seen an 
increased occurrence of ADR in drugs administered against 
asthma, arthrosis, anemia and nervous disorders (anxiety, 
depression, insomnia), appearing significant differences for 
the last three. This ADR increase to these treatments can be 
explained in some sense for the following reasons.
Regarding to arthrosis, it is a degenerative joint disease that 
causes cartilage wear. Pain, stiffness and functional disabil-
ity take place19. The main treatment consists in adminis-
tration of analgesic-antiinflammatory drugs. Paracetamol 
and non-steroidal antiinflammatory drugs (NSAIDs) are 
among these drugs and they are widely used19. The latter 
are drugs which suppress the synthesis of cyclooxygenase 
enzyme (COX). This enzyme converts arachidonic acid 
(which is obtained from membrane phospholipids) to dif-
ferent eicosanoids compounds. Prostaglandins, thrombox-
anes and leukotrienes are among these compounds, and 
they are important mediators of inflammatory processes 
and others20-24. Thus, inhibiting the synthesis of COX, we 
reduce the levels of these mediators and therefore inflam-
mation decreases. However, the isoenzyme COX 1, which 
is the constitutive isoform in our organism, participates in 
body homeostasis, keeping the integrity of the gastric mu-
cosa, among other functions. Therefore, the suppression of 
COX by NSAIDs is associated with several gastrointestinal 
disorders: esophagitis, gastritis, mucosal erosions, peptic 
ulcer, esophageal stricture, alterations in gut permeability, 
etc. NSAID gastrointestinal pathology accounts for over 
70000 hospitalizations and over 7000 deaths annually in 
the United States25. It is estimated that one in every five 
patients treated with NSAIDs for more than three months, 
develop gastric ulcers 21.
Another pathology which presented greater percentage of 
ADR is anemia. This disorder usually produces a decrease 
in the number of red blood cells. It is due mainly to deficient 
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levels of iron and its treatment is, therefore, administration 
of iron salts26. These iron compounds, such as ferrous sul-
fate, generate gastrointestinal disorders, which often result 
in low adherence27. Constipation and diarrhea are common 
disorders. Other symptoms include poor appetite, dark 
colored stools, nausea and vomiting. Such gastrointestinal 
disorders are due to high oxidative potential of iron which 
can result in the formation of reactive oxygen species28.
Regarding the treatment of nervous disorders, we included 
in that group: anxiety, depression and insomnia. Benzodi-
azepines are the main treatment for anxiety and insomnia 
while for depression disorder selective serotonin reuptake 
inhibitors (SSRIs) are the most frequently prescribed anti-
depressants. It is due to their superior clinical efficacy, ef-
fectiveness, tolerability and safety compared to tricyclic 
antidepressants or monoamino oxidase inhibitors29, 30.
On the one hand, benzodiazepines are drugs which act on 
the central nervous system, enhancing the inhibitory action 
of neurotransmitter GABA. Thus, it generates a hypnotic, 
anticonvulsant, sedative, muscle relaxant and amnesic ac-
tion. By its action mechanism also generates numerous ad-
verse effects such as sedation, reduced alertness, fatigue, 
headache, drowsiness, ataxia, confusion, depression, diz-
ziness, etc.29, 31-34. On the other hand, SSRIs work by selec-
tively blocking the presynaptic reuptake of serotonin in the 
brain stem and spinal cord, thereby making more seroto-
nin available, which in turn improves mood and behavior. 
Nevertheless, some adverse drug reactions can arise during 
SSRI treatment as nausea, diarrhea, headache, insomnia, 
nervousness, tachycardia etc.29, 30, 35. In this way, we can see 
that since these drugs act on the central nervous system, 
they produce lots of effects on the organism, and therefore, 
they are among the treatments that generate more ADR in 
our study.
Finally, about asthma, it is a chronic allergic respiratory dis-
ease characterized by inflammation of bronchial walls and 
reversible airway obstruction36, 37. Asthma is a long-term 
disease that has no cure. The goal of asthma treatment is to 
control the symptoms. There are two types of treatments, 
long-term and short term control drugs. Most of the people 
who have asthma need to take long-term control medicines 
daily to avoid and prevent symptoms, and all people who 
have asthma need quick-relief medicines to help relieve 
asthma symptoms that may flare up. Inhaled corticoster-
oids are the preferred medicine for long-term control of 
asthma, and inhaled short-acting β2-agonists are the first 
choice for quick relief. Concerning to inhaled corticoster-
oids, besides the beneficial effects, thrush frequently occurs 
and if taken for long periods, these medicines raise your 
risk to suffer from cataracts and osteoporosis38.
This reasoning about drugs which result in more ADR, also 
explain that the most frequent symptoms were gastroin-
testinal symptoms (60% of patients), followed by nervous 
disorders (24.6%), since they are the problems which are 
generated by three of four groups of drugs that more ADR 
produce in relation to the number of patients. Studies made 
in Spain and United States, found nervous disorders and 
gastrointestinal symptoms among the more frequency al-
terations caused by ADRs as well25, 39. 
CONCLUSION
Therapeutic groups which produce more commonly ADRs 
are those for arthrosis, anemia, nervous disorders and asth-
ma. In addition, symptoms which are more frequent when 
patients suffer from an ADR are gastrointestinal and nerv-
ous disorders. This is in accordance with the usual side ef-
fects of mentioned treatments due to its action mechanism. 
Health professionals should inform about it, so that they 
are more alert to a possible emergence of an ADR in these 
types of treatment and will provide sufficient information 
to empowder patients in order to detect themselves to be 
suffering an ADR. This would facilitate ADR detection and 
would avoid serious consequences to both patients’ health 
and health economic costs.
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